MariMed (MRMD) director receives 166,985 RSUs in lieu of cash fees

Rhea-AI Filing Summary

MariMed Inc. director Eva Selhub reported an equity compensation transaction involving restricted stock units (RSUs). On December 15, 2025, 166,985 RSUs converted into the same number of shares of MariMed common stock at a stated price of $0, reflecting the non-cash nature of the award. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 under an award agreement between MariMed and Selhub. According to the filing, these RSUs were granted in lieu of cash for a portion of her fees for serving on the Board of Directors, and she beneficially owned 482,671 shares of common stock directly after the transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Selhub Eva M.D.

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	12/15/2025		M		166,985	A	$0(1)	482,671	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	12/15/2025		A			166,985	(2)	(2)	Common Stock, par value $.001 per share	166,985	$0	0	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. The RSUs were granted on December 5, 2025 and vested in full on December 15, 2025 in accordance with the terms of the award agreement between the Issuer and the Reporting Person.

Remarks:

The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.

	/s/ Eva Selhub	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MariMed (MRMD) director Eva Selhub report?

Director Eva Selhub reported the conversion of 166,985 RSUs into the same number of shares of MariMed Inc. common stock on December 15, 2025 at a stated price of $0.

How many MariMed (MRMD) shares does the reporting person own after this Form 4 transaction?

Following the reported transaction, the filing states that the reporting person beneficially owned 482,671 shares of MariMed common stock directly.

When were the MariMed (MRMD) restricted stock units granted and when did they vest?

The filing explains that the 166,985 RSUs were granted on December 5, 2025 and vested in full on December 15, 2025 in accordance with the award agreement.

Why did MariMed (MRMD) grant RSUs to the director instead of paying cash?

The remarks section states that the RSUs were granted in lieu of cash as payment for a portion of the reporting person's fees for serving on MariMed's Board of Directors.

What is the conversion ratio of MariMed (MRMD) RSUs to common stock in this filing?

The explanation of responses notes that the RSUs convert to shares of common stock on a one-for-one basis, so each RSU became one share of MariMed common stock.

Does the MariMed (MRMD) Form 4 show any RSUs remaining after the transaction?

Table II reports 0 derivative securities beneficially owned following the transaction, indicating that no RSUs remained outstanding after the 166,985 units converted into common shares.